Caris Life Sciences, Inc. CAI
At closeNov 6, 2026, 4:26 PM EST
After hours · Nov 6, 4:26 PM ET
- YTD
- -6.49%
- 1 year
- +2.52%
- Market cap
- 7.24B
- Revenue (ttm)
- 1.05B
- Profit margin
- 9.16%
- EPS (ttm)
- 1.66
- Shares out
- 286.78M
- P/E ratio
- 15.20
- Forward P/E
- 67.58
- YTD return
- -6.49%
- 1-year return
- +2.52%
- Volume
- 10.24M
- Avg volume
- 4.70M
- Open
- 26.41
- Previous close
- 26.03
- Day's range
- 24.09 – 26.57
- 52-week range
- 14.19 – 36.50
- Analysts
- Buy
- Price target
- 32.46 (+28.7%)
- Earnings date
- Feb 25, 2027
5D -9.13 (-26.57%)
Key statistics
- Enterprise value
- 7.16B
- PEG ratio
- 0.00
- Price / sales
- 6.90
- Price / book
- 11.31
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 27.00%
- Free cash flow
- -25.86M
- Total cash
- 767.38M
- Total debt
- 463.02M
- Return on equity
- 17.19%
- Short % of float
- 11.39%
- 50-day average
- 29.50
- 200-day average
- 21.67
Analyst view
Consensus: buy
- Target (low)
- 22.00
- Target (mean)
- 32.46
- Target (high)
- 38.00
- Strong buy1
- Buy9
- Hold4
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate 0.11353.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | 0.12 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | 0.02814 | 0.05 | +0.02 | +77.68% |
| Aug 5, 2026 | Jun 30, 2026 | 0.00587 | -0.0023 | -0.01 | -139.18% |
| May 7, 2026 | Mar 31, 2026 | -0.02 | -0.0018 | +0.02 | +91.00% |
| Feb 26, 2026 | Dec 31, 2025 | 0.01 | 0.28 | +0.27 | +2,700.00% |
| Nov 5, 2025 | Sep 30, 2025 | -0.08 | 0.08 | +0.16 | +200.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2026 | TD Cowen | main | Buy | Buy |
| Nov 5, 2026 | BTIG | reit | Buy | Buy |
| Oct 27, 2026 | BTIG | main | Buy | Buy |
| Oct 19, 2026 | Canaccord Genuity | main | Hold | Hold |
| Oct 14, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 13, 2026 | TD Cowen | main | Buy | Buy |
About Caris Life Sciences, Inc.
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- carislifesciences.com
News
Citigroup Maintains Buy on Caris Life Sciences, Raises Price Target to $36 
TD Cowen Maintains Buy on Caris Life Sciences, Raises Price Target to $38 
VIX Spikes 39% as AI Tech Rout Wipes Out $2.2 Trillion: Stock Market Today 
Zillow Posts Downbeat Q3 Results, Joins HubSpot, Snap And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
Caris Life Sciences, Inc. (CAI) Q3 2026 Earnings Call Transcript 
Caris Life Sciences Q3 Earnings Call Highlights 
Caris Life Sciences,?Inc. (CAI) Q3 Earnings and Revenues Top Estimates 
Caris Life Sciences Q3 2026 Earnings Call Transcript 
Caris Life Sciences Raises FY2026 Sales Guidance from $1.030B-$1.040B to $1.040B-$1.050B vs $1.030B Est
Your note
Sign in to keep a note on CAI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAPT I LTD | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jun 19, 2025 | 0 |
| BRILLE BRIAN J. | Officer and Director | Sale | Sep 16, 2026 | 730,303 |
| CASTLEMAN PETER M | Director | Stock Award(Grant) | Aug 13, 2026 | 10,683,700 |
| HALBERT DAVID D | Chief Executive Officer | Stock Award(Grant) | Mar 5, 2026 | 123,640,000 |
| HALBERT JON S. | Director | Stock Award(Grant) | Aug 13, 2026 | 1,490,410 |
| JOHANSEN LAURA I. | Director | Stock Award(Grant) | Aug 13, 2026 | 343,897 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 10.78% | 30,923,878 | 780.21M | Jun 29, 2026 |
| J. H. Whitney Equity Partners VI, LLC | 3.93% | 11,256,615 | 284.00M | Jun 29, 2026 |
| Coatue Management LLC | 3.42% | 9,819,992 | 247.76M | Jun 29, 2026 |
| Braidwell LP | 2.88% | 8,256,032 | 208.30M | Jun 29, 2026 |
| Sixth Street Partners Management Company, L.P. | 2.55% | 7,327,041 | 184.86M | Jun 29, 2026 |
| PointState Capital LP | 2.38% | 6,828,835 | 172.29M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Contrafund | 1.52% | 4,366,372 | 110.16M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.41% | 4,047,820 | 102.13M | Jun 29, 2026 |
| JPMorgan Trust II-JPMorgan Mid Cap Growth Fund | 1.16% | 3,320,983 | 83.79M | Jun 29, 2026 |
| SmallCap World Fund Inc | 1.05% | 3,007,137 | 75.87M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.02% | 2,921,307 | 73.70M | Jun 29, 2026 |
| T. Rowe Price Mid-Cap Growth Fund, Inc. | 0.94% | 2,702,379 | 68.18M | Jun 29, 2026 |